This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Infinity Supports Blood Cancer Awareness Month With Launch Of Sparks Of Inspiration, A Campaign To Honor People Affected By Blood Cancer

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is observing National Blood Cancer Awareness Month, joining patients, healthcare providers and patient organizations in raising public awareness of blood cancers and the need for continued research for novel treatment options. In support of patients and their loved ones, Infinity is launching the Sparks of Inspiration campaign. Throughout the month of September, Infinity encourages the submission of stories along with photos or illustrations to honor friends, family members and loved ones affected by blood cancer. For each submission received, Infinity will make a donation of $10 to the Leukemia & Lymphoma Society (LLS), the world's largest voluntary health organization dedicated to blood cancers.

To learn more about Sparks of Inspiration and submit your tribute, please visit www.infi.com.

“We are grateful for the support from Infinity, which highlights our shared goal of advancing new treatment options for patients affected by blood cancers,” said John Walter, president and CEO of LLS. “Blood Cancer Awareness Month is the right platform to create a sense of urgency about the need to continue investing in lifesaving treatments and cures. As there are no means of prevention of or early detection for most blood cancers, we must focus on cures.”

“Infinity is committed to discovering and developing new medicines for patients with difficult-to-treat conditions, including blood cancers,” commented Pedro Santabarbara, M.D., Ph.D. chief medical officer at Infinity. “Through this campaign, we are honoring the courage and strength of patients with blood cancers and their families. We are pleased to support the Leukemia & Lymphoma Society’s mission of finding cures for blood cancers and improving the quality of life for patients and families.”

Infinity is developing IPI-145, a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of certain blood cancers.

“Early Phase 1 data of IPI-145 has shown encouraging signs of clinical activity across a broad range of blood cancers. I am excited to be involved in ongoing trials of IPI-145 and look forward to further evaluation of this investigational drug,” said Ian Flinn, M.D., Ph.D., director, hematologic malignancies program, Sarah Cannon Research Institute, and an investigator for these clinical studies of IPI-145. “New targeted agents in development, such as IPI-145, have the potential not only to expand therapeutic options for patients but also to reduce or delay the need for chemotherapy.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,856.78 -278.94 -1.54%
S&P 500 2,071.26 -29.78 -1.42%
NASDAQ 4,927.37 -55.4390 -1.11%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs